Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
BETTA PHARMACEUTICALS CO., LTD currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, indicating that each pending matter is being reviewed by a different individual. Despite this variety in examiners, the portfolio is concentrated within 2 distinct art units.
JONATHAN DAVIS MAHLUM is the busiest examiner, though he is only responsible for 1 pending office action. This distribution shows that the workload is perfectly balanced across the 4 distinct examiners. The concentration in 2 distinct art units suggests that while examiners differ, the technical focus remains narrow within the Biotechnology & Pharmaceuticals sector. Practitioners should prepare for diverse examiner perspectives, as no single examiner handles more than 1 pending office action.
The limited number of 2 distinct art units may offer some consistency in the general examination guidelines applied to the portfolio. Navigating 4 distinct examiners requires a flexible approach to individual examiner preferences while maintaining a consistent technical narrative. This structure suggests that while the technical scope is limited to 2 art units, the subjective interpretation of that scope will vary across 4 different reviewers.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 9d |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | HERNANDEZ, JACKSON J | 55d |
| 18706666 | BICYCLIC COMPOUND AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | — |
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706666 | BICYCLIC COMPOUND AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | — | §102§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | 9d | Pending | Dec 20, 2023 |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | 55d | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial